This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Denamur, E.
Right arrow Articles by Matic, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Denamur, E.
Right arrow Articles by Matic, I.

 Previous Article  |  Next Article 

Journal of Bacteriology, January 2002, p. 605-609, Vol. 184, No. 2
0021-9193/01/$04.00+0     DOI: 10.1128/JB.184.2.605-609.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

High Frequency of Mutator Strains among Human Uropathogenic Escherichia coli Isolates

Erick Denamur,1 Stéphane Bonacorsi,2 Antoine Giraud,3 Patrick Duriez,1,3 Farida Hilali,4 Christine Amorin,1 Edouard Bingen,2 Antoine Andremont,4 Bertrand Picard,5 François Taddei,3 and Ivan Matic3*

INSERM U 458,1 Laboratoire d’Étude de Génétique Bactérienne dans les Infections de l’Enfant (EA3105),2 Hôpital Robert Debré, INSERM EPI 9916, Faculté de Médecine Necker-Enfants Malades, Université René Descartes—Paris V,3 INSERM EPI 9933, Hôpital Bichat-Claude Bernard, AP-HP, Paris,4 Laboratoire de Microbiologie, Hôpital Morvan, Brest, France5

Received 18 June 2001/ Accepted 24 October 2001


arrow
ABSTRACT
 
By using a panel of 603 commensal and pathogenic Escherichia coli and Shigella isolates, we showed that mutation rates of strains vary considerably among different ecotypes. Uropathogenic strains had the highest frequency of mutators, while strains from patients with bacteremia had the lowest mutation rates. No correlation between the mutation rates and antibiotic resistance was observed among the studied strains.


arrow
INTRODUCTION
 
Bacterial populations with a high level of genetic variability have a higher probability of survival in constantly changing environments (18). Since genetic variability is generated mostly by mutagenesis, bacterial strains with high mutation rates are expected to have higher capacities for adaptation. Such strains are favored by selection when the advantage of beneficial mutations is greater than the cost of being a mutator due to the overproduction of lethal and deleterious mutations (6, 17, 19). Mutator strains, having a defective mismatch repair system, have indeed been observed in natural populations of Escherichia coli, Salmonella enterica, Neisseria meningitidis, and Pseudomonas aeruginosa (5, 7, 10, 12). Because most of these isolates are pathogens, it has been hypothesized that mutator and hyperrecombination phenotypes may accelerate the evolution of pathogenic strains by, e.g., increasing the variation of surface antigens, as well as by facilitating the acquisition of pathogenic determinants and antibiotic resistance. Indeed, it has been observed that the levels of resistance to antibiotics were significantly higher in mutator than in nonmutator pathogenic P. aeruginosa isolates (10) and that mismatch repair-deficient N. meningitidis strains displayed high phase variation rates (12).

However, from the available data, it is not clear whether high mutation rates are particularly important for the evolution of pathogens in general or for the evolution of only some pathogenic groups (5, 7, 10, 11). Furthermore, a mutator phenotype may not be specific to pathogens, since mutators have also been observed in commensal populations (7). In order to examine the link between a particular bacterial lifestyle, mutation rate, and antibiotic resistance, we used a collection of 603 human E. coli (including Shigella) isolates, either commensal isolates or ones involved in various pathologies, such as enteroinvasive and enterohemorrhagic diseases, urinary tract infection (UTI), bacteremia, pus production from miscellaneous infections, and newborn meningitis (NBM). A detailed list of strains is given in Table 1.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Strains studied


arrow
Variations of mutation rates.
 
The mutation rates of the studied strains were estimated by monitoring the strains’ capacities to generate mutations conferring resistance to rifampin in at least six independent cultures for each strain (Fig. 1 and 2), as described previously (16). Between 102 and 103 cells from an overnight culture were inoculated onto nitrocellulose filters (NC45; Schleicher and Schuell) laid on plates containing fresh 869 medium (NaCl, 5 g/liter; Bacto Tryptone, 10 g/liter; yeast extract, 5 g/liter; agar, 15 g/liter). The plates were incubated at 37°C for 24 h. The cells were resuspended in 1 ml of 869 medium and incubated for 1 h at 37°C to allow for rifampin resistance expression. Appropriate dilutions were then spread on 869 medium plates with rifampin (100 µg/ml; Sigma) or without. The rifampin-resistant mutants were counted after 24 h at 37°C.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1. Mutator strains belonging to different human E. coli and Shigella commensal and pathogenic groups. Bacterial strains are grouped according to their origins and the different pathologies in which they have been involved, including bacteremia strains (n = 93), strains isolated from pus (n = 30), commensal strains (n = 217), enteroinvasive strains (n = 86), enterohemorrhagic strains (n = 26), NBM strains (n = 60), and UTI strains (n = 91). In addition, all pathogenic strains are presented as one group in order to facilitate a comparison of that group with commensal strains. Strains were considered mutators when they exhibited frequencies of mutations conferring resistance to rifampin (100 µg/ml) that were 10-fold higher than the median value of mutagenesis (5.04 x 10-9) observed for all studied strains (n = 603) (10-fold mutators). Strains that displayed a >50-fold increase in mutagenesis were considered strong mutators (50-fold mutators). Percentages of mutator strains were calculated for every group of studied strains. UTI strains had significantly higher (according to the {chi}2 test) fractions (*) of 10- and 50-fold mutators than commensal strains (P = 0.005 and P = 0.001 for 10- and 50-fold mutators, respectively), as well as other pathogens (P = 0.001 and P = 0.001 for 10- and 50-fold mutators, respectively).



View larger version (50K):
[in this window]
[in a new window]
  		FIG. 2. Variability of mutation rates of human E. coli and Shigella isolates after elimination of mutators. The mean value (± standard error) of mutation frequency, after removal of those for 10- and 50-fold mutators (see legend to Fig. 1), is shown for each group.

We found mutators among commensals and pathogens, but the frequencies of mutators in these two groups of strains were not significantly different (Fig. 1 and 2). However, when pathogenic strains were analyzed as members of different ecotypes, mutator strains were found to occur significantly more frequently among UTI strains than they did among commensals and also more frequently among UTI strains than among all other pathogenic strain groups. It is interesting to note that bacteremia strains, which include urosepsis isolates, had the smallest fraction of mutator strains but also, significantly (according to the t test), the lowest mutation rates of all strains (Fig. 1 and 2). Strains isolated from pus also have significantly lower mutation rates than all other strains (except bacteremia strains) (Fig. 1 and 2).

We confirmed that strains generating rifampin-resistant mutants at a high rate correspond to generalized mutators by measuring the frequencies of the mutations that confer resistance to the following four additional antibiotics (at indicated concentrations) in at least six independent cultures for each strain: nalidixic acid (40 µg/ml), phosphomycin (30 µg/ml), spectinomycin (100 µg/ml), and streptomycin (100 µg/ml) (all from Sigma) (Fig. 3).



View larger version (42K):
[in this window]
[in a new window]
  		FIG. 3. Capacities of mutator strains to generate mutations conferring resistance to different antibiotics. The results are presented as mean values (± standard errors) for mutator (>10-fold increase in mutagenesis; n = 21) and nonmutator (n = 47) strains.


arrow
Why do UTI strains have the highest frequency of mutator strains?
 
One possible explanation for the high frequency of mutators in UTI strains is that mutator strains belong to one clone which has increased in frequency in populations of UTI strains due to the action of positive selection. However, we found that strong UTI mutator strains belong to different E. coli phylogenetic groups: A, B2, and D. Furthermore, by sequencing metabolic genes (trpA, trpB, putP, and papB), we have also confirmed that the group B2 UTI mutator strains (most abundant among UTI strains) did not belong to the same clone (data not shown). Therefore, our data suggest that there is no correlation between mutation rate and phylogenetic group.

The possibility that UTI mutators are better adapted to growth in urine, due to the acquisition of adaptive mutations or to a pleiotropic effect linked to a modified DNA repair ability, seems to be marginal at best, since both mutator and nonmutator UTI strains grow easily in fresh urine (with no significant difference between them), reaching concentrations of about 108 CFU/ml (data not shown).

Another possibility is that mutators are less frequently counterselected in the urinary tract than in other body compartments. It has been demonstrated that mutators can suffer a reduction of fitness due to the accumulation of deleterious mutations (3, 4). One of the measurable phenotypes of fitness reduction is loss of the capacity to grow on minimal synthetic medium. This handicap might be less important, at least in the short run, in urine, as suggested by a higher incidence of auxotrophs (25%) among UTI strains than among strains from fecal samples (5.8%) (13). However, we did not observe more auxotrophs among UTI mutator strains than among UTI nonmutators (data not shown).

Finally, it is possible that UTI mutators are selected because they generate mutations that increase adaptation to the urinary tract at a higher rate than that generated by nonmutators. For example, it has been shown that point mutations in fimH genes increase binding of the adhesin to monomannose residues, structures that are abundant in the urothelial glycoproteins, conferring increased virulence in a UTI mouse model (15) as well as an increased capacity for biofilm formation (14). However, this hypothesis must be confirmed by in vivo and in vitro reconstruction experiments.


arrow
Antibiotic resistance.
 
It is possible that antibiotic treatments contribute to selection of the mutators, as has been demonstrated in in vitro experiments (6). Mutators can be favored under such conditions because they generate antibiotic resistance-conferring mutations at a higher rate than that generated by nonmutators (Fig. 3). In addition, they also generate more mutations that compensate for the fitness reduction associated with antibiotic resistance (1a).

Since most of the antibiotics we used to demonstrate the mutator phenotype of the strains were not of medical relevance, we performed standard antibiogram testing of the activities of amikacin, amoxicillin, amoxicillin-clavulanic acid, ceftazidime, ciprofloxacin, nalidixic acid, trimethoprim-sulfamethoxazole, and phosphomycin (8), as well as a determination of the MICs of ceftazidime, amikacin, and ciprofloxacin (9) for 26 mutator and 42 nonmutator strains. The majority of mutator strains yielded colonies inside the growth inhibition zone (squatter colonies), while no nonmutator strains exhibited that phenotype (Fig. 4). The presence of squatter colonies reflects the high frequency of mutations conferring resistance to antibiotics. The squatter colonies were not observed only when ceftazidime or ciprofloxacin was used. However, mutator strains are not more resistant than nonmutators are, and no mutator strain was resistant to multiple antibiotics (data not shown).



View larger version (104K):
[in this window]
[in a new window]
  		FIG. 4. Squatter colonies inside growth inhibition zone. Growth inhibitory zones for nalidixic acid (disk 1), amoxicillin (disk 2), and phosphomycin (disk 3) are presented for nonmutator (A) and mutator (B) strains. Note the presence of squatter colonies for the mutator strain only.

Furthermore, additional UTI strains that are resistant to quinolones (n = 9) or that have an overexpressed cephalosporinase (n = 7) (both resistance mechanisms resulting from point mutations) did not show a higher mutation rate than nonmutator strains (data not shown). Therefore, it can be concluded that antibiotics are probably not the major selective pressure that favors mutator strains in natural E. coli populations.


arrow
Conclusions.
 
Although UTI strains have the highest frequency of mutators, the link between high mutation rates and pathogenicity cannot be generalized. Other pathogenic groups do not have more mutators than commensal organisms do. Furthermore, bacteremia and pus isolates have very low mutation rates (Fig. 1 and 2). The reason for the observed high frequency of mutators in populations of UTI strains remains to be determined.

Our finding that mutators are present in almost all studied groups of E. coli ecotypes supports recently published observations which suggest that the majority of E. coli strains repeatedly pass through periods of high mutation rates during their evolutionary history, regardless of whether they are commensal or pathogenic or to which phylogenetic group they belong (2).


arrow
ACKNOWLEDGMENTS
 
We thank Jean-Pierre Coutenceau for technical assistance and E. Stewart and O. Tenaillon for critical reading of the manuscript.

This work was supported by grants from the Programme de Recherche Fondamentale en Microbiologie et Maladies Infectieuses et Parasitaires—MENRT and the Programme Environnement et Santé—MATE.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: INSERM EPI 9916, Faculté de Médecine Necker-Enfants Malades, Université Rene Descartes—Paris V, 156 Rue de Vaugirard, 75730 Paris Cedex 15, France. Phone: (33) 1 40 61 53 25. Fax: (33) 1 40 61 53 22. E-mail: matic{at}necker.fr. Back


arrow
REFERENCES
 
    1
  1. Bingen, E., B. Picard, N. Brahimi, S. Mathy, P. Desjardins, J. Elion, and E. Denamur. 1998. Phylogenetic analysis of Escherichia coli strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains. J. Infect. Dis. 177:642–650.[Medline]
    2. 1
  2. Bjorkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479–1482.[Abstract/Free Full Text]
    3. 2
  3. Denamur, E., G. Lecointre, P. Darlu, O. Tenaillon, C. Acquaviva, C. Sayada, I. Sunjevaric, R. Rothstein, J. Elion, F. Taddei, M. Radman, and I. Matic. 2000. Evolutionary implications of the frequent horizontal transfer of mismatch repair genes. Cell 103:711–721.[CrossRef][Medline]
    4. 2
  4. Duriez, P., O. Clermont, S. Bonacorsi, E. Bingen, A. Chaventre, J. Elion, B. Picard, and E. Denamur. 2001. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations. Microbiology (Reading) 147:1671–1676.[Abstract/Free Full Text]
    5. 3
  5. Funchain, P., A. Yeung, J. L. Stewart, R. Lin, M. M. Slupska, and J. H. Miller. 2000. The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness. Genetics 154:959–970.[Abstract/Free Full Text]
    6. 4
  6. Giraud, A., I. Matic, O. Tenaillon, A. Clara, M. Radman, M. Fons, and F. Taddei. 2001. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 291:2606–2608.[Abstract/Free Full Text]
    7. 4
  7. Hilali, F., R. Ruimy, P. Saulnier, C. Barnabé, C. Lebouguénec, M. Tibayrenc, and A. Andremont. 2000. Prevalence of virulence genes and clonality in Escherichia coli strains that cause bacteremia in cancer patients. Infect. Immun. 68:3983–3989.[Abstract/Free Full Text]
    8. 5
  8. LeClerc, J. E., B. Li, W. L. Payne, and T. A. Cebula. 1996. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274:1208–1211.[Abstract/Free Full Text]
    9. 6
  9. Mao, E. F., L. Lane, J. Lee, and J. H. Miller. 1997. Proliferation of mutators in a cell population. J. Bacteriol. 179:417–422.[Abstract/Free Full Text]
    10. 7
  10. Matic, I., M. Radman, F. Taddei, B. Picard, C. Doit, E. Bingen, E. Denamur, and J. Elion. 1997. Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 277:1833–1834.[Free Full Text]
    11. 8
  11. National Committee for Clinical Laboratory Standards. 1993. Performance for antimicrobial disk susceptibility tests, 5th ed. Approved standard M2-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
    12. 9
  12. National Committee for Clinical Laboratory Standards. 1998. Performance for antimicrobial susceptibility testing, 8th informational supplement. M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    13. 9
  13. Ochman, H., and R. K. Selander. 1984. Standard reference strains of Escherichia coli from natural populations. J. Bacteriol. 157:690–693.[Abstract/Free Full Text]
    14. 10
  14. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251–1254.[Abstract/Free Full Text]
    15. 11
  15. Picard, B., P. Duriez, S. Gouriou, I. Matic, E. Denamur, and F. Taddei. 2001. Mutator natural Escherichia coli isolates have an unusual virulence phenotype. Infect. Immun. 69:9–14.[Abstract/Free Full Text]
    16. 11
  16. Picard, B., J. S. Garcia, S. Gouriou, P. Duriez, N. Brahimi, E. Bingen, J. Elion, and E. Denamur. 1999. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect. Immun. 67:546–553.[Abstract/Free Full Text]
    17. 12
  17. Richardson, A. R., and I. Stojiljkovic. 2001. Mismatch repair and the regulation of phase variation in Neisseria meningitidis. Mol. Microbiol. 40:645–655.[CrossRef][Medline]
    18. 13
  18. Robeson, J. P., R. M. Goldschmidt, and R. D. Curtiss. 1980. Potential of Escherichia coli isolated from nature to propagate cloning vectors. Nature 283:104–106.[CrossRef][Medline]
    19. 13
  19. Rolland, K., N. Lambert-Zechovsky, B. Picard, and E. Denamur. 1998. Shigella and enteroinvasive Escherichia coli strains are derived from distinct ancestral strains of E. coli. Microbiology (Reading) 144:2667–2672.[Abstract/Free Full Text]
    20. 14
  20. Schembri, M. A., and P. Klemm. 2001. Biofilm formation in a hydrodynamic environment by novel FimH variants and ramifications for virulence. Infect. Immun. 69:1322–1328.[Abstract/Free Full Text]
    21. 15
  21. Sokurenko, E. V., V. Chesnokova, D. E. Dykhuizen, I. Ofek, X. R. Wu, K. A. Krogfelt, C. Struve, M. A. Schembri, and D. L. Hasty. 1998. Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin. Proc. Natl. Acad. Sci. USA 95:8922–8926.[Abstract/Free Full Text]
    22. 16
  22. Taddei, F., I. Matic, and M. Radman. 1995. Cyclic AMP-dependent SOS induction and mutagenesis in resting bacterial populations. Proc. Natl. Acad. Sci. USA 92:11736–11740.[Abstract/Free Full Text]
    23. 17
  23. Taddei, F., M. Radman, J. Maynard-Smith, B. Toupance, P. H. Gouyon, and B. Godelle. 1997. Role of mutators in adaptive evolution. Nature 387:700–702.[CrossRef][Medline]
    24. 18
  24. Taddei, F., M. Vulic, M. Radman, and I. Matic. 1997. Genetic variability and adaptation to stress, p.271–290. In R. Bijlsma and V. Loeschcke (ed.), Environmental stress, adaptation, and evolution, vol. EXS 83. Birkhäuser Verlag, Basel, Switzerland.
    25. 19
  25. Tenaillon, O., B. Toupance, H. Le Nagard, F. Taddei, and B. Godelle. 1999. Mutators, population size, adaptive landscape and the adaptation of asexual populations of bacteria. Genetics 152:485–493.[Abstract/Free Full Text]

Journal of Bacteriology, January 2002, p. 605-609, Vol. 184, No. 2
0021-9193/01/$04.00+0     DOI: 10.1128/JB.184.2.605-609.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hidalgo, A., Schliessmann, A., Molina, R., Hermoso, J., Bornscheuer, U. T. (2008). A one-pot, simple methodology for cassette randomisation and recombination for focused directed evolution. Protein Eng Des Sel 21: 567-576 [Abstract] [Full Text]  
  • Simms, A. N., Mobley, H. L. T. (2008). Multiple Genes Repress Motility in Uropathogenic Escherichia coli Constitutively Expressing Type 1 Fimbriae. J. Bacteriol. 190: 3747-3756 [Abstract] [Full Text]  
  • Marcobal, A. M., Sela, D. A., Wolf, Y. I., Makarova, K. S., Mills, D. A. (2008). Role of Hypermutability in the Evolution of the Genus Oenococcus. J. Bacteriol. 190: 564-570 [Abstract] [Full Text]  
  • Joo, L. M., Macfarlane-Smith, L. R., Okeke, I. N. (2007). Error-Prone DNA Repair System in Enteroaggregative Escherichia coli Identified by Subtractive Hybridization. J. Bacteriol. 189: 3793-3803 [Abstract] [Full Text]  
  • Cattoir, V., Lesprit, P., Lascols, C., Denamur, E., Legrand, P., Soussy, C.-J., Cambau, E. (2006). In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid. J Antimicrob Chemother 58: 1054-1057 [Abstract] [Full Text]  
  • Odds, F. C., Davidson, A. D., Jacobsen, M. D., Tavanti, A., Whyte, J. A., Kibbler, C. C., Ellis, D. H., Maiden, M. C. J., Shaw, D. J., Gow, N. A. R. (2006). Candida albicans Strain Maintenance, Replacement, and Microvariation Demonstrated by Multilocus Sequence Typing.. J. Clin. Microbiol. 44: 3647-3658 [Abstract] [Full Text]  
  • Ellington, M. J., Livermore, D. M., Pitt, T. L., Hall, L. M. C., Woodford, N. (2006). Mutators among CTX-M {beta}-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 58: 848-852 [Abstract] [Full Text]  
  • Hall, L. M. C., Henderson-Begg, S. K. (2006). Hypermutable bacteria isolated from humans - a critical analysis.. Microbiology 152: 2505-2514 [Abstract] [Full Text]  
  • Warner, D. F., Mizrahi, V. (2006). Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clin. Microbiol. Rev. 19: 558-570 [Abstract] [Full Text]  
  • Chen, S. L., Hung, C.-S., Xu, J., Reigstad, C. S., Magrini, V., Sabo, A., Blasiar, D., Bieri, T., Meyer, R. R., Ozersky, P., Armstrong, J. R., Fulton, R. S., Latreille, J. P., Spieth, J., Hooton, T. M., Mardis, E. R., Hultgren, S. J., Gordon, J. I. (2006). Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: A comparative genomics approach. Proc. Natl. Acad. Sci. USA 103: 5977-5982 [Abstract] [Full Text]  
  • Le Chat, L., Fons, M., Taddei, F. (2006). Escherichia coli mutators: selection criteria and migration effect. Microbiology 152: 67-73 [Abstract] [Full Text]  
  • Andre, J.-B., Godelle, B. (2006). The Evolution of Mutation Rate in Finite Asexual Populations. Genetics 172: 611-626 [Abstract] [Full Text]  
  • Baquero, M.-R., Galan, J. C., del Carmen Turrientes, M., Canton, R., Coque, T. M., Martinez, J. L., Baquero, F. (2005). Increased Mutation Frequencies in Escherichia coli Isolates Harboring Extended-Spectrum {beta}-Lactamases. Antimicrob. Agents Chemother. 49: 4754-4756 [Abstract] [Full Text]  
  • Denamur, E., Tenaillon, O., Deschamps, C., Skurnik, D., Ronco, E., Gaillard, J. L., Picard, B., Branger, C., Matic, I. (2005). Intermediate Mutation Frequencies Favor Evolution of Multidrug Resistance in Escherichia coli. Genetics 171: 825-827 [Abstract] [Full Text]  
  • Gillespie, S. H., Basu, S., Dickens, A. L., O'Sullivan, D. M., McHugh, T. D. (2005). Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 56: 344-348 [Abstract] [Full Text]  
  • Trong, H. N., Prunier, A.-L., Leclercq, R. (2005). Hypermutable and Fluoroquinolone-Resistant Clinical Isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2098-2101 [Abstract] [Full Text]  
  • Nilsson, A. I., Kugelberg, E., Berg, O. G., Andersson, D. I. (2004). Experimental Adaptation of Salmonella typhimurium to Mice. Genetics 168: 1119-1130 [Abstract] [Full Text]  
  • Galan, J.-C., Tato, M., Baquero, M.-R., Turrientes, C., Baquero, F., Martinez, J.-L. (2004). Fosfomycin and Rifampin Disk Diffusion Tests for Detection of Escherichia coli Mutator Strains. J. Clin. Microbiol. 42: 4310-4312 [Abstract] [Full Text]  
  • Watson, M. E. Jr, Burns, J. L., Smith, A. L. (2004). Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150: 2947-2958 [Abstract] [Full Text]  
  • Baquero, M.-R., Nilsson, A. I., del Carmen Turrientes, M., Sandvang, D., Galan, J. C., Martinez, J. L., Frimodt-Moller, N., Baquero, F., Andersson, D. I. (2004). Polymorphic Mutation Frequencies in Escherichia coli: Emergence of Weak Mutators in Clinical Isolates. J. Bacteriol. 186: 5538-5542 [Abstract] [Full Text]  
  • Smania, A. M., Segura, I., Pezza, R. J., Becerra, C., Albesa, I., Argarana, C. E. (2004). Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa. Microbiology 150: 1327-1338 [Abstract] [Full Text]  
  • Travis, E. R., Travis, J. M. J. (2004). Mutators in Space: The Dynamics of High-Mutability Clones in a Two-Patch Model. Genetics 167: 513-522 [Abstract] [Full Text]  
  • Kozitskaya, S., Cho, S.-H., Dietrich, K., Marre, R., Naber, K., Ziebuhr, W. (2004). The Bacterial Insertion Sequence Element IS256 Occurs Preferentially in Nosocomial Staphylococcus epidermidis Isolates: Association with Biofilm Formation and Resistance to Aminoglycosides. Infect. Immun. 72: 1210-1215 [Abstract] [Full Text]  
  • Miller, K., O'Neill, A. J., Chopra, I. (2004). Escherichia coli Mutators Present an Enhanced Risk for Emergence of Antibiotic Resistance during Urinary Tract Infections. Antimicrob. Agents Chemother. 48: 23-29 [Abstract] [Full Text]  
  • Komp Lindgren, P., Karlsson, A., Hughes, D. (2003). Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections. Antimicrob. Agents Chemother. 47: 3222-3232 [Abstract] [Full Text]  
  • Gustafsson, I., Sjolund, M., Torell, E., Johannesson, M., Engstrand, L., Cars, O., Andersson, D. I. (2003). Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother 52: 645-650 [Abstract] [Full Text]  
  • Bjedov, I., Tenaillon, O., Gerard, B., Souza, V., Denamur, E., Radman, M., Taddei, F., Matic, I. (2003). Stress-Induced Mutagenesis in Bacteria. Science 300: 1404-1409 [Abstract] [Full Text]  
  • Li, B., Tsui, H.-C. T., LeClerc, J. E., Dey, M., Winkler, M. E., Cebula, T. A. (2003). Molecular analysis of mutS expression and mutation in natural isolates of pathogenic Escherichia coli. Microbiology 149: 1323-1331 [Abstract] [Full Text]  
  • Gogarten, J. P., Doolittle, W. F., Lawrence, J. G. (2002). Prokaryotic Evolution in Light of Gene Transfer. Mol Biol Evol 19: 2226-2238 [Abstract] [Full Text]  
  • Notley-McRobb, L., Seeto, S., Ferenci, T. (2002). Enrichment and Elimination of mutY Mutators in Escherichia coli Populations. Genetics 162: 1055-1062 [Abstract] [Full Text]  
  • Ito-Harashima, S., Hartzog, P. E., Sinha, H., McCusker, J. H. (2002). The tRNA-Tyr Gene Family of Saccharomyces cerevisiae: Agents of Phenotypic Variation and Position Effects on Mutation Frequency. Genetics 161: 1395-1410 [Abstract] [Full Text]  
  • de Visser, J. A. G. M. (2002). The fate of microbial mutators. Microbiology 148: 1247-1252 [Full Text]  
  • Giraud, A., Matic, I., Radman, M., Fons, M., Taddei, F. (2002). Mutator Bacteria as a Risk Factor in Treatment of Infectious Diseases. Antimicrob. Agents Chemother. 46: 863-865 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Denamur, E.
Right arrow Articles by Matic, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Denamur, E.
Right arrow Articles by Matic, I.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»